This Page No Longer Exists

You will now be re-directed to our new home at

If this page does not re-direct within 10 seconds, click on the link above

Diabetes Reference
by Tom Bartol, RN-C, MN, FNP, CDE


Abbasi, F. et. al. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients: Evidence for a central role of adipose tissue. Diabetes Care, 1997; 20(12)1863-1869.

American Diabetes Association. Clinical Practice Recommendations 2000. Diabetes Care, 2000; Vol.23, supp 1.

American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 1997; 20:1183-1197.

Antonucci T, Whitcomb R, McLain R, et. al. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care, 1997;20:188-193.

Aviles-Santa L, Sinding J, & Raskin P. Effects of metformin in patients with poorly controlled, insulin- treated type 2 diabetes mellitus. Ann Intern Med, 1999;131:182-188.

Bell PM. Clinical significance of insulin resistance. Diabet Med, 1996;13:504-509.

Berkowitz K, Peters R, Kjos SL, et. al. Effect of troglitazone on insulin sensitivity and pancreatic B-Cell function in women at high risk for NIDDM. Diabetes, 1996;45:1572-1579.

Brewer, KW et. al. Slicing the pie: Correlating HbA1c values with average blood glucose values in a pie chart form. Diabetes Care, 1998; 21(2)209-212.

Cefalu, WT, Parker, TB, & Johnson, CR. Validity of serum fructosamine as index of short-term glycemic control in diabetic outpatients. Diabetes Care, 1988; 11(8)662-664.

Cerasi, E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM: is a divorce possible? Diabetologia, 1995; 38:992-997.

Conniff, RF et. al.. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by Acarbose in patients with NIDDM: A placebo-controlled dose-comparison study. Diabetes Care, 1995; 18:817-824.

Dagogo-Jack, S & Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic Interventions. Arch Intern Med, 1997;157:1802-1817.

Davidson, MB & Peters, AL. An overview of metformin in the treatment of type 2 diabetes mellitus. American Journal of Med, 1997; 102:99-110.

DeFronzo, RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281- 303.

DeFronzo, RA & Goodman, AM and the Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. NEJM, 1995; 333(9)541-549.

Després, J et. al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med, 1996; 334:952-967.

Draeger, K et. al. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): A double-blind comparison with glibenclamide. Horm. Metab. Res., 1996; 28:419-425.

Dunn CJ & Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs, 1995;49:721-749.

Ferrannini, E. et. al. Insulin resistance, hyperinsulinemia, and blood pressure: Role of age and obesity. Hypertension, 1997; 30:1144-1149.

Ferrannini, E. et. al. Insulin resistance and hypersecretion in obesity. J. Clin. Invest., 1997; 100(5)11661173.

Fontbonne A, Charles MA, Juhan-Vague I, et. al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. Diabetes Care, 1996;19:920-926.

Fonseca V, Rosenstock J, Patwardhan R, et. al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. JAMA, 2000;283:1695-1702.

Garber AJ, Duncan TG, Goodman, AM, et. al. Efficacy of metformin in type II diabetse: results of a double-blind, placebo-controlled, dose response trial. AM J Med, 1997;102:491-497.

Garber, AJ. Metformin therapy for type II diabetes mellitus. Pharmacy and Therapeutics, September 1995.

Ghazzi MN, Perez JE, Antonucci TK, et. al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM Diabetes, 1997;46:433-439.

Goldberg, RB et. al. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care, 1996; 19:849-856.

Garancini, M.P. et. al. Factors related to glycemic control in IDDM and insulin-treated NIDDM patients in current practice: A comparison of care policies. Diabetes Care, 1997; 20(11) 1659-1663.

Goldstein, DE et. al. Tests of glycemia in diabetes. Diabetes Care, 1995; 18(6)896-909.

Granberry MC, Schneider EF, & Fonseca VA. The role of troglitazone in treating the insulin resistance syndrome. Pharmacotherapy, 1998;18:973-987.

Haffner, SM & Miettinen, H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am. J. Med., 1997; 103:152-162.

Haffner, SM et. al. Prospective analysis of the insulin resistance syndrome (Syndrome X). Diabetes, 1992; 41:715-722.

Haller, H et. al. The role of hyperglycemia on hyperinsulinemia in the pathogenesis of diabetic angiopathy. Clinical Nephrology, 1996; 46:246-255.

Harris, MI. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care, 1993, 16:642-652.

Inzucchi, SE et. al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. NEJM, 1998; 338(13)867-872.

Iwamoto, Y et. al. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care, 1996; 19:151-156.

Iwamoto, Y. et. al. Effect of combination therapy of troglitazone and sulphonylureas in patients with type 2 diabetes who were poorly controlled by sulphonylurea therapy alone. Diabetic Medicine, 1996; 13:365-370.

Jha RJ. Thiazolidinediones-the new insulin enhancers. Clin and Exper Hypertension, 1999;21(1&2):157- 166.

Johnson MD, Campbell LK, & Campbell RK. Troglitazone: Review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. Ann Pharmacother, 1998;32:337-348.

Johnson, JL, Wolf, SL, & Kabadi, UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. Arch Intern Med, 1996; 156:259-264.

King, GL. The role of hyperglycaemia and hyperinsulinaemia in causing vascular dysfunction in diabetes. Annals of Medicine, 1996; 28:427-432.

Kuehnle HF. New therapeutic agents for the treatment of NIDDM. Exp Clin Endocrinol Diabetes, 1996;104:93-101.

Laakso, M. Insulin resistance and coronary heart disease. Current Opinion in Lipidology, 1996; 7:217-226.

Laakso, M. How good a marker is insulin level for insulin resistance? American Journal of Epidemiology, 1993; 137(9)959-965.

Laakso, M. et. al. Essential hypertension and insulin resistance in non-insulin dependent diabetes. European Journal of Clinical Investigation, 1989; 19:518-526.

Lebovitz HE. Effects of oral antihyperglycemic agents in modifying macrovascular risk factors in type 2 Diabetes. Diabetes Care, 1999;21(suppl 3):c41-c44.

Lettieri JT & Dain B. Effects of Beano on the tolerability and pharmacodynamics of Acarbose. Clin Ther, 1998;20:497-504.

Lithell, HO. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertension, 1996; 9:150S-154S.

Mayer-Davis, EJ et. al. Intensity and amount of physical activity in relation to insulin sensitivity: The insulin resistance atherosclerosis study. JAMA, 1998; 279(9)669-674.

Misbin, RI et. al. Lactic acidosis in patients with diabetes treated with metformin. NEJM, 1998; 338(4)265-266.

Nagi, DK & Yudkin, JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care, 1993; 16(4)621-629.

Nolan, JJ et. al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. NEJM, 1994; 331:1188-1193.

Nozue T, Michishita I, Minagawa F, et. al. Troglitazone directly increases HDL cholseterol levels. Diabetes Care, 1999;22:355-356.

Ogihara T, Rakugi H, Ikegami H, et. al. Enhancement of insulin sensitivigty by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens, 1995;8:316-320.

Reaven GM. Role of insulin resistance in human disease (Syndrome X): an expanded definition. Ann Rev Med, 1993;44:121-131.

Reaven, GM. Banting lecture 1988: Role of insulin resistance in human disease. Diabetes, 1988; 37:1595-1607.

Rosenstock J, Brown A, Fischer J, et. al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care, 1998;21:2050-2055.

Saltiel, AR & Olefsky, JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes, 1996; 45:1661-1669.

Schwartz, S. et. al. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. NEJM, 1998; 338(13)861-866.

Sprietsma, JE & Schuitemaker, GE. Diabetes can be prevented by reducing insulin production. Medical Hypotheses, 1994; 42:15-23.

Stout, RW. Insulin and atheroma: 20-yr perspective. Diabetes Care, 1990; 13:631-654.

Stumvoll, M et. al. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. NEJM, 1995; 333:550-554.

Subramaniam S. The emerging role of thiazolidinediones in the treatment of diabetes-mellitus and related disorders. Clin and Exper Hypertension, 1999;21(1&2):121-126.

Sulkin, T. et. al. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care, 1997;20:925-928.

Turner RC, Cull CA, Frighi V, et. al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999;281:2005-2012.

UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 1998; 352:837-853.

UK Prospective Diabetes Study Group (UKPDS). Effect of intensive blood-glucose control with metformin on omplications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet, 1998; 352:854-865.

Whitcomb, WR & Saltiel, AR. Thiazolidinediones. Exp. Opin. Invest. Drugs, 1995; 4:1299-1309.

Wiman, B. Plamsinogen Activator Inhibitor 1 (PAI-1) in plasma: It's role in thrombotic disease. Thrombosis and Haemostasis, 1995; 74(1)71-76.

Yarnell, JWG et. al. Insulin in ischaemic heart disease: are associations explained by Triglyceride concentrations? The Caerphilly prospective study. British Heart Journal, 1994; 71:293-296.

Yki-Jarvinen H, Ryysy L, Nikkila K, et. al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med, 1999;130:389-396.

Yudkin, JS. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Annals of Medicine, 1996; 28:433-438.

[an error occurred while processing this directive]


NP Central
10024 S.E. 240th St., Suite #102, Kent, WA 98031
Phone: 253.852.9042 Fax: 253.852.7725
NP Central Gateway

Use of this section indicates you agree to the Terms of Use.
Copyright 1994-2003 NP Central

Last updated: November 23, 2000